SCHEMBL2783283

SCHEMBL2783283

Nc1cc2c(cc1C(=O)O)OCCO2

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.64
ALDH1A1 P00352 4/20 0.64
MAPT P10636 7/20 0.57
TDP1 Q9NUW8 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
LMNA P02545 1/20 0.57
KMT2A Q03164 3/20 0.54
MEN1 O00255 2/20 0.54
GAA P10253 1/20 0.54
IDO1 P14902 1/20 0.46
GFER P55789 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
HSD17B10 Q99714 2/20 0.43
TSHR P16473 1/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29699971 1.00 KDM4E (0.64) KDM4EALDH1A1MAPTTDP1SMN1; SMN2
SCHEMBL15639033 0.92 SMN1; SMN2 (0.64) KDM4EALDH1A1MAPTTDP1SMN1; SMN2
SCHEMBL29590055 0.88 ALDH1A1 (0.50) KDM4EALDH1A1MAPTTDP1SMN1; SMN2
SCHEMBL7018429 0.88 ALDH1A1 (0.50) KDM4EALDH1A1MAPTTDP1SMN1; SMN2
SCHEMBL7275882 0.85 SMN1; SMN2 (0.62) KDM4EALDH1A1MAPTTDP1SMN1; SMN2
SCHEMBL31127883 0.82 KDM4E (0.67) KDM4EALDH1A1MAPTTDP1SMN1; SMN2
SCHEMBL21721961 0.82 KDM4E (0.67) KDM4EALDH1A1MAPTTDP1SMN1; SMN2
SCHEMBL17782570 0.82 FABP4 (0.48) KDM4EALDH1A1MAPTTDP1SMN1; SMN2
SCHEMBL3521748 0.80 MAPT (0.75) KDM4EALDH1A1MAPTTDP1SMN1; SMN2
SCHEMBL363189 0.78 KDM4E (0.61) KDM4EALDH1A1MAPTTDP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2232243-B1 REAL-TIME METHOD FOR THE DETECTION OF VIABLE MICRO-ORGANISMS TNO (NL) 2015-12-16 EP claimed
US-8986946-B2 Real-time method for the detection of viable micro-organisms NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) 2015-03-24 US claimed
US-20120122147-A1 REAL-TIME METHOD FOR THE DETECTION OF VIABLE MICRO-ORGANISMS NEDERLANDSE ORGANISATIE VOOR TOEGEPAST- NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) 2012-05-17 US claimed
WO-2010151131-A2 APPARATUS FOR DETECTING VIABLE MICROORGANISMS OR SPORES IN A SAMPLE AND USE THEREOF. NEDERLANDSE ORGANISATIE VOOR TOEGEPAST- NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) 2010-12-29 WO claimed
EP-2232243-A1 REAL-TIME METHOD FOR THE DETECTION OF VIABLE MICRO-ORGANISMS Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO (NL) 2010-09-29 EP claimed
WO-2009082218-A1 REAL-TIME METHOD FOR THE DETECTION OF VIABLE MICRO-ORGANISMS NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) 2009-07-02 WO claimed
EP-4037687-B1 BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS MOLECULAR SKIN THERAPEUTICS INC (US) 2025-10-29 EP disclosed
US-12281123-B2 Benzoxazinone compounds as KLK5/7 dual inhibitors MOLECULAR SKIN THERAPEUTICS, INC. (US) 2025-04-22 US disclosed
US-20240067658-A1 BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS ML Bio Solutions Inc. 2024-02-29 US disclosed
US-20240067658-A1 BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS ML Bio Solutions Inc. 2024-02-29 US disclosed
US-20240067658-A1 BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS ML Bio Solutions Inc. 2024-02-29 US disclosed
US-20230257390-A1 COMPOUNDS WHICH INHIBIT RNA POLYMERASE AND THEIR USE LIEBER INSTITUTE, INC. 2023-08-17 US disclosed
US-11643420-B2 Benzoxazinone compounds as KLK5/7 dual inhibitors MOLECULAR SKIN THERAPEUTICS, INC. (US) 2023-05-09 US disclosed
EP-2903965-B1 N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS ORION CORP (FI) 2017-03-01 EP disclosed
US-9533952-B2 N-prop-2-ynyl carboxamide derivatives and their use as TRPA1 antagonists ORION CORPORATION (FI) 2017-01-03 US disclosed
US-20150376130-A1 N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS Orlon Corporation (FI) 2015-12-31 US disclosed
EP-2903965-A1 N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS Orion Corporation (FI) 2015-08-12 EP disclosed
WO-2014053694-A1 N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS ORION CORPORATION (FI) 2014-04-10 WO disclosed
WO-2010151131-A2 APPARATUS FOR DETECTING VIABLE MICROORGANISMS OR SPORES IN A SAMPLE AND USE THEREOF. NEDERLANDSE ORGANISATIE VOOR TOEGEPAST- NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) 2010-12-29 WO disclosed
WO-2007048064-A2 AMINO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS, INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376130-A1 N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS TRPA1, TRPV1, TRPV2 KDM4E 3536/4885ALDH1A1 1295/4885MAPT 1793/4885
US-12281123-B2 Benzoxazinone compounds as KLK5/7 dual inhibitors KLK5, KLK1, KLK2 KDM4E 377/4885ALDH1A1 1224/4885MAPT 2106/4885
US-20230257390-A1 COMPOUNDS WHICH INHIBIT RNA POLYMERASE AND THEIR USE POLR2E, POLR2H, POLRMT KDM4E 3247/4885ALDH1A1 1795/4885MAPT 418/4885
US-11643420-B2 Benzoxazinone compounds as KLK5/7 dual inhibitors KLK5, KLK1, KLK2 KDM4E 377/4885ALDH1A1 1224/4885MAPT 2106/4885
US-20240067658-A1 BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS KLK5, KLK1, KLK2 KDM4E 377/4885ALDH1A1 1224/4885MAPT 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.